Sjögren's syndrome: The 140-subject study will be conducted by collaboration partner Gilead Sciences (NASDAQ:GILD). Sjögren's is a systemic inflammatory disorder characterized by extensive dryness, commonly in the eyes and mouth.
Ankylosing spondylitis (AS): The 100-subject study, TORTUGA, will be conducted by Galapagos. AS is a systemic and progressive form of inflammatory arthritis.
Psoriatic arthritis: The 124-subject trial, EQUATOR, will also be conducted by Galapagos.